Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma. [electronic resource]
Producer: 20141006Description: 689-95 p. digitalISSN:- 1532-1827
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized -- pharmacology
- Antineoplastic Agents -- pharmacology
- Breast Neoplasms -- drug therapy
- Cell Line, Tumor
- Central Nervous System Neoplasms -- drug therapy
- Chemotherapy, Adjuvant
- Class I Phosphatidylinositol 3-Kinases
- DNA Mutational Analysis
- Drug Resistance, Neoplasm
- Enzyme Activation
- Female
- Humans
- Kaplan-Meier Estimate
- Middle Aged
- Molecular Targeted Therapy
- Phosphatidylinositol 3-Kinases -- genetics
- Receptor, ErbB-2 -- metabolism
- Signal Transduction
- Trastuzumab
- src-Family Kinases -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.